HIV 临床试验市场 - 全球产业规模、份额、趋势、机会和预测，按阶段、按研究设计、按赞助商、按地区和竞争进行细分，2020-2030 年预测

2024 年全球爱滋病毒临床试验市值为 15.8 亿美元，预计到 2030 年将达到 22 亿美元，预测期内复合年增长率为 5.62%。全球爱滋病毒临床试验市场涵盖广泛的研究计画和投资，旨在开发创新的爱滋病毒治疗、疗法和预防解决方案。製药公司、研究机构和医疗保健组织透过进行临床前和临床试验来评估新药和治疗方案的安全性、有效性和长期影响，在推动这个市场方面发挥着至关重要的作用。这些试验对改善患者治疗效果、降低传播率和提高爱滋病毒感染者的生活品质做出了重大贡献。

该市场的关键方面之一是抗逆转录病毒疗法 (ART) 的不断发展，它有助于控制病毒并防止其发展为爱滋病。临床试验对于测试下一代 ART、长效注射剂和新型治疗策略（包括基于免疫的疗法和基因编辑技术）至关重要。此外，人们正在广泛研究爱滋病毒疫苗、暴露前预防（PrEP）和单株抗体等预防措施，以抑制新的感染。政府机构、非营利组织和私营部门实体不断增加的投资推动了市场的发展，这些投资资助了旨在找到有效治疗方法或彻底消除病毒的研究计画。临床试验设计的进步，例如分散试验和自适应方法，也提高了效率和患者参与度。儘管存在监管复杂性和道德考量等挑战，全球爱滋病毒临床试验市场仍然是爱滋病毒研究的基石，为全球对抗这一持续的健康挑战做出了贡献。

主要市场驱动因素

爱滋病毒/爱滋病疫情持续存在

主要市场挑战

耻辱与歧视

主要市场趋势

长效抗爱滋病毒疗法 (ART)

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球 HIV 临床试验市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依阶段划分（第一阶段、第二阶段、第三阶段、第四阶段）
  • 依研究设计分类（介入性研究、观察性研究、扩大准入研究）
  • 按赞助商分类（製药和生物製药公司、非营利组织、其他）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第 6 章：北美 HIV 临床试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 7 章：欧洲 HIV 临床试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区 HIV 临床试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美 HIV 临床试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲爱滋病毒临床试验市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Syneos Health Inc
• PPD Inc
• IQVIA Inc
• PAREXEL International Corp
• ICON PLC
• WuXi AppTec Co Ltd
• Janssen Global Services LLC
• Gilead Sciences Inc
• GSK PLC
• Charles River Laboratories Inc

第 15 章：策略建议

第16章 调査会社について・免责事项

Global HIV Clinical Trials Market was valued at USD 1.58 Billion in 2024 and is expected to reach USD 2.20 Billion by 2030 with a CAGR of 5.62% during the forecast period. The Global HIV Clinical Trials Market encompasses a wide range of research initiatives and investments aimed at developing innovative treatments, therapies, and preventive solutions for HIV. Pharmaceutical companies, research institutions, and healthcare organizations play a crucial role in driving this market by conducting preclinical and clinical trials to assess the safety, efficacy, and long-term impact of new drugs and treatment regimens. These trials contribute significantly to improving patient outcomes, reducing transmission rates, and enhancing the quality of life for individuals living with HIV.

One of the key aspects of this market is the continuous evolution of antiretroviral therapies (ART), which help manage the virus and prevent its progression to AIDS. Clinical trials are essential for testing next-generation ARTs, long-acting injectables, and novel therapeutic strategies, including immune-based therapies and gene editing techniques. Additionally, preventive measures such as HIV vaccines, pre-exposure prophylaxis (PrEP), and monoclonal antibodies are being extensively studied to curb new infections. The market is driven by rising investments from government agencies, nonprofit organizations, and private sector entities that fund research initiatives aimed at finding a functional cure or complete eradication of the virus. Advances in clinical trial designs, such as decentralized trials and adaptive methodologies, are also enhancing efficiency and patient participation. Despite challenges such as regulatory complexities and ethical considerations, the Global HIV Clinical Trials Market remains a cornerstone of HIV research, contributing to the global fight against this persistent health challenge.

Key Market Drivers

Persistence of the HIV/AIDS Epidemic

The HIV/AIDS epidemic has been a global health crisis for decades, affecting millions of people worldwide. According to the IAVI report, an estimated 39.9 million people were living with HIV/AIDS in 2023, with 1.3 million new HIV cases recorded during the year. While significant progress has been made in understanding and managing the virus, the persistence of HIV/AIDS continues to drive research and development efforts. According to the National AIDS Control Organization (NACO) HIV estimates for 2023, India's overall HIV epidemic remains low, with an adult prevalence rate of 0.20%. However, certain states continue to report significantly higher prevalence rates, including Mizoram (2.73%) and Nagaland (1.37%), followed closely by Manipur (0.87%). Additionally, Andhra Pradesh (0.62%), Telangana (0.44%), Meghalaya (0.43%), Karnataka (0.42%), and Punjab (0.42%) recorded adult prevalence rates exceeding 0.40%. Mizoram and Nagaland have the highest number of districts with a prevalence rate above 1%. Among the 96 districts with prevalence rates ranging from 0.40% to 1%, 75 are located in Andhra Pradesh, Karnataka, Manipur, Meghalaya, Punjab, and Telangana. While adult HIV prevalence has shown a declining trend across most states and union territories over the years, the increasing prevalence in Punjab and certain northeastern states (excluding Nagaland and Manipur) remains a concern. This persistence not only underscores the ongoing need for effective treatments and preventive measures but also plays a pivotal role in boosting the growth of the Global HIV Clinical Trials Market. The persistence of the HIV/AIDS epidemic creates a continuous demand for innovative solutions. Despite the availability of antiretroviral therapy (ART), new challenges such as drug resistance, long-term side effects, and accessibility issues persist. These challenges drive researchers and pharmaceutical companies to seek better treatments, including new drug formulations, combination therapies, and alternative treatment strategies.

As HIV continues to evolve, drug-resistant strains of the virus have emerged. This poses a significant threat to individuals living with HIV and underscores the need for clinical trials to develop new drugs and treatment regimens that can effectively combat drug-resistant variants. The persistence of HIV/AIDS means that diverse patient populations with varying demographics, medical histories, and viral strains are still affected.for instance, Despite a low prevalence rate, India continues to bear a substantial HIV burden, with an estimated 2.544 million people living with HIV (PLHIV) in 2023.

Clinical trials need to include a wide range of participants to ensure that new treatments and preventive measures are effective across different groups. This diversity is essential for achieving a comprehensive understanding of HIV and tailoring therapies to specific needs.

HIV affects diverse populations across the globe. Increased funding supports the expansion of clinical trials into regions with high HIV prevalence, including low- and middle-income countries. This geographical diversity is crucial for ensuring that research findings are applicable to a broad range of individuals. Funding enables researchers to implement effective recruitment and retention strategies for clinical trial participants. Financial incentives, community engagement programs, and support services for trial participants become more feasible, resulting in better enrollment and participation rates. With increased funding, clinical trials can become more patient-centric. This means taking into account the needs and preferences of trial participants, including diverse demographics, cultural backgrounds, and medical histories. Patient-centric trials are more likely to yield relevant and practical results. Additional funding allows for the exploration of promising drug candidates and preventive measures that might otherwise go untested due to budget constraints. Researchers can take risks on unconventional approaches, potentially uncovering groundbreaking solutions.

Public awareness campaigns inform individuals about the importance of HIV clinical trials and how they can participate. When more people are aware of these trials, they are more likely to consider participating, thereby expanding the pool of potential participants. This inclusivity ensures that clinical trial results are more representative of diverse populations.

Key Market Challenges

Stigma and Discrimination

Stigma and discrimination surrounding HIV continue to pose significant challenges in the field of clinical trials. Many individuals fear that participating in a trial will expose their HIV status, leading to social isolation, workplace discrimination, or even loss of employment and housing. This fear is particularly pronounced in regions where HIV-related stigma is deeply entrenched in societal and cultural norms. As a result, many eligible candidates hesitate to enroll in clinical studies, limiting the diversity of participants and potentially skewing research outcomes. Additionally, stigma can discourage open conversations about trial participation between healthcare providers and patients, further reducing enrollment rates. Addressing these concerns requires strong advocacy, confidentiality measures, and public awareness campaigns to reduce misconceptions about HIV.

Key Market Trends

Long-Acting Antiretroviral Therapies (ART)

Long-acting antiretroviral therapies (ART) represent a transformative advancement in HIV treatment, addressing key challenges related to adherence and treatment efficacy. Traditional ART requires daily oral administration, which can be burdensome for patients, leading to missed doses and the potential for viral resistance. Long-acting formulations, such as injectables and implants, offer a solution by significantly reducing dosing frequency. By administering ART every few weeks or months, these formulations enhance treatment adherence and minimize the stigma associated with daily pill intake.

Current clinical trials are evaluating the safety, efficacy, and pharmacokinetics of various long-acting ART formulations. For instance, cabotegravir and rilpivirine, a combination of long-acting injectable ART, have demonstrated promising results in maintaining viral suppression with monthly or bimonthly dosing. Additionally, pharmaceutical companies are developing subcutaneous implants capable of delivering ART over extended periods, further improving patient convenience. Beyond treatment adherence, long-acting ART may have significant public health benefits, particularly for populations facing social and economic barriers to consistent healthcare access. People living in remote areas, those with unstable housing, or individuals with mental health challenges may benefit immensely from reduced dosing schedules. However, challenges such as potential drug resistance, injection site reactions, and manufacturing scalability remain critical areas of ongoing research.

The development of long-acting ART aligns with global efforts to control the HIV epidemic by improving treatment outcomes and reducing transmission rates. As more long-acting formulations advance through late-stage trials, their potential integration into routine HIV care could redefine treatment strategies, making HIV management more effective and accessible on a global scale.

Key Market Players

• PPD Inc
• IQVIA Inc
• PAREXEL International Corp
• ICON PLC
• Syneos Health Inc
• WuXi AppTec Co Ltd
• Janssen Global Services LLC
• Gilead Sciences Inc
• GSK PLC
• Charles River Laboratories Inc

Report Scope:

In this report, the Global HIV Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV Clinical Trials Market, By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

HIV Clinical Trials Market, By Study Design:

• Interventional Studies
• Observational Studies
• Expanded Access Studies

HIV Clinical Trials Market, By Sponsor:

• Pharmaceutical & Biopharmaceutical Companies
• Non-Profit Organizations
• Others

HIV Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HIV Clinical Trials Market.

Available Customizations:

Global HIV Clinical Trials market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global HIV Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.2. By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies)
  • 5.2.3. By Sponsor (Pharmaceutical & Biopharmaceutical Companies, Non-Profit Organizations, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America HIV Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Study Design
  • 6.2.3. By Sponsor
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States HIV Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Study Design
      • 6.3.1.2.3. By Sponsor
  • 6.3.2. Mexico HIV Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Study Design
      • 6.3.2.2.3. By Sponsor
  • 6.3.3. Canada HIV Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Study Design
      • 6.3.3.2.3. By Sponsor

7. Europe HIV Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Study Design
  • 7.2.3. By Sponsor
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France HIV Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Study Design
      • 7.3.1.2.3. By Sponsor
  • 7.3.2. Germany HIV Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Study Design
      • 7.3.2.2.3. By Sponsor
  • 7.3.3. United Kingdom HIV Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Study Design
      • 7.3.3.2.3. By Sponsor
  • 7.3.4. Italy HIV Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Study Design
      • 7.3.4.2.3. By Sponsor
  • 7.3.5. Spain HIV Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Study Design
      • 7.3.5.2.3. By Sponsor

8. Asia-Pacific HIV Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Study Design
  • 8.2.3. By Sponsor
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China HIV Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Study Design
      • 8.3.1.2.3. By Sponsor
  • 8.3.2. India HIV Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Study Design
      • 8.3.2.2.3. By Sponsor
  • 8.3.3. South Korea HIV Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Study Design
      • 8.3.3.2.3. By Sponsor
  • 8.3.4. Japan HIV Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Phase
      • 8.3.4.2.2. By Study Design
      • 8.3.4.2.3. By Sponsor
  • 8.3.5. Australia HIV Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Phase
      • 8.3.5.2.2. By Study Design
      • 8.3.5.2.3. By Sponsor

9. South America HIV Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Study Design
  • 9.2.3. By Sponsor
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil HIV Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Study Design
      • 9.3.1.2.3. By Sponsor
  • 9.3.2. Argentina HIV Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Study Design
      • 9.3.2.2.3. By Sponsor
  • 9.3.3. Colombia HIV Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Study Design
      • 9.3.3.2.3. By Sponsor

10. Middle East and Africa HIV Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Study Design
  • 10.2.3. By Sponsor
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa HIV Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Study Design
      • 10.3.1.2.3. By Sponsor
  • 10.3.2. Saudi Arabia HIV Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Study Design
      • 10.3.2.2.3. By Sponsor
  • 10.3.3. UAE HIV Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Study Design
      • 10.3.3.2.3. By Sponsor

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Syneos Health Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. PPD Inc
• 14.3. IQVIA Inc
• 14.4. PAREXEL International Corp
• 14.5. ICON PLC
• 14.6. WuXi AppTec Co Ltd
• 14.7. Janssen Global Services LLC
• 14.8. Gilead Sciences Inc
• 14.9. GSK PLC
• 14.10. Charles River Laboratories Inc

15. Strategic Recommendations

16. About Us & Disclaimer